A library of natural sesquiterpene and phenolic compounds from Petasites japonicus are being investigated through different computational techniques to study their ability to target BMP. Lipinski rule, ADMET, molecular docking studies and metabolism were used to reach promising candidates with proposed activity against BMP. Four sesquiterpenes (kablicin, petisinol, bakkenolide D and bakkenolide IIIa) and four phenolic compounds exhibited drug-like properties (caffeic acid, petasiphenol, petasitesin A and petasitesin B), so they deserve further clinical exploration as bone loss modulators. The phenolic compounds specially fukinolic acid and petasiphenol showed lower binding energy with both BMPRIA and BMPRII than Icariin agonist and sesquiterpenes. Bakkenolide IIIa showed dual potential on both BMPRIA and BMPRII with binding energies equal – 7.82 and – 9.9 Kcal/mol respectively, which is more better score than Betulinic acid agonist. This research is focusing on plant-human interactions and exploring the ability of plant constituents to modulate a human protein such as BMP.
Background Despite its wide use, cisplatin induces serious multiorgan toxicity via stimulating vicious inflammatory, oxidative stress and apoptotic cascades. Betulin is a naturally occurring triterpene that has been shown to protect against cisplatin‐induced nephrotoxicity, yet its protective effect against cisplatin‐induced hepato‐ and cardiotoxicity has not been studied. Aim of the work Here we investigated the potential protective effect of betulin against cisplatin‐induced hepatotoxicity in rats and the potential underlying mechanism of this effect. Methods Induction of cisplatin acute hepatotoxicity was achieved by single intraperitoneal injection of 10 mg/kg in the middle of the experimental model timeframe. Betulin treatment (8 mg/kg) was intraperitoneally injected daily for total period of 10 days. Results Treatment with betulin significantly improved biochemical liver functions as indicated by restoring cisplatin disrupted levels of serum Aspartate transaminase (AST), Alanine transaminase (ALT), albumin and total bilirubin. In addition, betulin significantly improved histopathological structural features of liver tissues and significantly reduced hepatic tissue fibrosis turnover. Betulin hepatoprotective effect was mediated via reducing cisplatin‐provoked oxidative stress, inflammation and apoptosis. Specifically, betulin increased hepatic total antioxidant capacity and decreased hepatic malondialdehyde levels compared to cisplatin group. In addition, betulin significantly attenuated cisplatin‐induced NOD‐like receptor pyrin domain‐containing protein 3 (NLRP3) inflammasome pathway activation as evident by downregulating hepatic tissue levels of NLRP3, caspase‐1 and interleukin‐1β (IL‐1β). Interestingly, despite of the cisplatin‐induced upregulation of the hepatic NLRP3 interacting protein, mitotic kinase NIMA‐related kinase 7 (Nek7), betulin did not induce any significant alteration of its levels in liver tissues. Betulin significantly reduced cisplatin‐induced apoptosis induction as indicated by significant reduction of the apoptotic proteins P53 and Bax, significant reduction of caspases‐8, ‐9 and ‐3 and upregulation of the anti‐apoptotic protein Bcl2. Conclusion To the best of our knowledge, this is the first study to address the hepatoprotective effect of betulin against cisplatin‐induced liver injury through modulation of inflammatory and apoptotic pathways.
Background Ulcerative colitis (UC) is a common inflammatory bowel disease. The importance of experimental models for investigating the pathogenic mechanisms and assessment of potential therapeutic agents for UC is well established. Betulin is a natural triterpene compound that has been reported to exert wide spectrum of pharmacological and biological activities. Aim of the work The present study aims to evaluate the potential therapeutic effect of betulin against acetic acid (AA)‐induced UC in rats. Material and methods Thirty adult Sprague Dawley rats were randomly assigned into three groups: normal control, UC and UC+betulin (8 mg/kg). UC was induced by intracolonic instillation of AA (3% v/v) in 0.9% saline in all study groups except for the normal group. Four days post instillation of AA, UC+betulin group was treated by intraperitoneal administration of betulin once daily for 14 consecutive days. Results Results showed that betulin attenuated AA‐induced UC as evident by reduced macroscopic scores, decreased serum C reactive protein (CRP) titer and lactate dehydrogenase (LDH) activity and attenuated histopathological hallmarks including mucosal necrosis, haemorrhage, congestion and inflammatory cells infiltration. Moreover, betulin treatment dampened colonic inflammatory status via downregulation of toll like receptor‐4 (TLR4)/Nuclear factor‐κB NF‐kB axis accompanied by reduction of colonic inflammatory cytokines tumor necrosis factor‐α (TNF‐α) and Interleukin‐6 (IL‐6) as well as CD68 immunostaining. Additionally, betulin administration suppressed signs of apoptosis as shown by reduced caspase‐3 and caspase‐8 immunostaining compared with UC group. Conclusion Our findings demonstrate a novel therapeutic effect of betulin against UC via suppression of TLR4/NF‐κB signalling.